Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 5/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | TPMT | P51580 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15515148 | 0.66 | HTR2A (0.50) | — | |
| SCHEMBL7401099 | 0.65 | HSD11B1 (0.40) | EPHX2CA1CA2L3MBTL1HSD11B1 | |
| SCHEMBL3071621 | 0.64 | HSD11B1 (0.43) | EPHX2L3MBTL1HSD11B1 | |
| SCHEMBL536531 | 0.61 | CXCR3 (0.44) | CXCR3EPHX2TP53CYP1A2CYP3A4 | |
| SCHEMBL2097717 | 0.61 | TPMT (0.44) | TPMTCA1CA2 | |
| Adamantane SCHEMBL28567812 | 0.61 | CHRM2 (0.40) | CXCR3EPHX2TP53CYP1A2CYP3A4 | |
| SCHEMBL4110715 | 0.60 | EPHX2 (0.68) | CXCR3EPHX2TP53CYP1A2CYP3A4 | |
| SCHEMBL2095874 | 0.60 | NPSR1 (0.54) | TPMTCA1CA2L3MBTL1KMT2A | |
| SCHEMBL28207613 | 0.59 | KDM4E (0.45) | EPHX2L3MBTL1KMT2A | |
| SCHEMBL13410874 | 0.59 | L3MBTL1 (0.56) | EPHX2TP53L3MBTL1HSD11B1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150217004-A1 | CARBAMATE COMPOUNDS AND METHODS OF USE IN DISEASES OF THE NERVOUS SYSTEM | TREVENTIS CORPORATION | 2015-08-06 | — | — | US | disclosed |
| WO-2014039526-A2 | CARBAMATE COMPOUNDS AND METHODS OF USE IN DISEASES OF THE NERVOUS SYSTEM | TREVENTIS CORPORATION (US) | 2014-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150217004-A1 | CARBAMATE COMPOUNDS AND METHODS OF USE IN DISEASES OF THE NERVOUS SYSTEM | CHAT, ACHE, HCRTR1 | CXCR3 2919/4885EPHX2 1919/4885TP53 3127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.